Type 2 diabetes. Endocrine, nutritional and metabolic diseases
Conditions
Interventions
Intervention 1: The intervention group receive 40 mg pantaprazole tablets twice daily for 12 weeks. Intervention 2: The control group receive placebo twice daily for 12 weeks.
Treatment - Drugs
Placebo
The intervention group receive 40 mg pantaprazole tablets twice daily for 12 weeks.
The control group receive placebo twice daily for 12 weeks
Sponsors
Research deputy of Tabriz University of Medical Sciences
Bone disease health center, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria : type II diabetes and oral blood glucose lowering drugs for at least 5 years; HbA1C level<8.5 percent; willing to participate in the study Exclusion Criteria: Presence of diabetic complications; use of insulin in the week before the study and during the study; pregnancy and lactation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma glucose levels. Timepoint: Before and 12 weeks after intervention. Method of measurement: Paraclinical.;Serum gastrtin levels. Timepoint: Before and 12 weeks after intervention. Method of measurement: Paraclinical.;HbA1C. Timepoint: Before and 12 weeks after intervention. Method of measurement: Paraclinical.;Serum insulin levels. Timepoint: Before and 12 weeks after intervention. Method of measurement: Paraclinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Frazad Najafipour
Tabriz University of Medical Sciences
Outcome results
None listed